<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39386114</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-7076</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>IJID regions</Title><ISOAbbreviation>IJID Reg</ISOAbbreviation></Journal><ArticleTitle>Dynamics of anti-SARS-CoV-2 antibodies in the Albanian population: Impact of infection- and vaccine-induced immunity during the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>100440</StartPage><MedlinePgn>100440</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100440</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijregi.2024.100440</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Understanding immune response dynamics during the COVID-19 pandemic is crucial for optimizing future vaccine strategies. This study investigated the infection- and vaccine-induced SARS-CoV-2 antibody responses in the Albanian population from August 2021 to August 2022.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This used a cross-sectional approach, analyzing two independent, randomly selected population samples over 1 year. Participants' demographic, health, vaccination, and COVID-19 data were collected, with blood samples assessed via enzyme linked immunosorbent assay for immunoglobulin G class anti-spike and anti-nucleocapsid antibodies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">By August 2022, all individuals receiving one vaccine dose achieved antibody levels comparable to those receiving two doses (median 7.71 index ratio [IR] vs 7.00 IR). In August 2021, those with previous COVID-19 infection receiving one vaccine dose showed median anti-spike immunoglobulin G levels of 7.22 IR compared with 4.84 IR in those without previous infection receiving two doses. However, individuals aged ≥61 years required two vaccine doses to achieve similar immune responses as younger individuals with one dose.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">These findings underscore the importance of hybrid immunity, suggesting one vaccine dose may suffice for individuals with previous COVID-19 infection, whereas older adults require additional doses for optimal protection. This study provides insights into humoral immune response dynamics, which is crucial for refining COVID-19 vaccination strategies in middle-income countries with low vaccination coverage and high infection rates.</AbstractText><CopyrightInformation>© 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sulcebe</LastName><ForeName>Genc</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Center of Biotechnology and Genetics, Academy of Sciences of Albania, Tirana, Albania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Medicine of Tirana, Tirana, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ylli</LastName><ForeName>Alban</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Medicine of Tirana, Tirana, Albania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Public Health, Tirana, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cenko</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Catholic University "Our Lady of Good Counsel" Tirana, Tirana, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurti-Prifti</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Center of Biotechnology and Genetics, Academy of Sciences of Albania, Tirana, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shyti</LastName><ForeName>Erkena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Research Center of Biotechnology and Genetics, Academy of Sciences of Albania, Tirana, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dashi-Pasholli</LastName><ForeName>Jonida</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Center of Biotechnology and Genetics, Academy of Sciences of Albania, Tirana, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazri</LastName><ForeName>Erina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Medicine of Tirana, Tirana, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seferi-Qendro</LastName><ForeName>Irena</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University of Medicine of Tirana, Tirana, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>Melissa J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>College of Public Health, George Mason University, Fairfax, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>IJID Reg</MedlineTA><NlmUniqueID>9918418183106676</NlmUniqueID><ISSNLinking>2772-7076</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Albanian population</Keyword><Keyword MajorTopicYN="N">Anti–SARS-CoV-2 antibodies</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 seroprevalence</Keyword><Keyword MajorTopicYN="N">Vaccination status</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39386114</ArticleId><ArticleId IdType="pmc">PMC11462266</ArticleId><ArticleId IdType="doi">10.1016/j.ijregi.2024.100440</ArticleId><ArticleId IdType="pii">S2772-7076(24)00111-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chowdhury MA, Hossain N, Kashem MA, Shahid MA, Alam A. Immune response in COVID-19: a review. J Infect Public Health. 2020;13:1619–1629. doi: 10.1016/j.jiph.2020.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.07.001</ArticleId><ArticleId IdType="pmc">PMC7359800</ArticleId><ArticleId IdType="pubmed">32718895</ArticleId></ArticleIdList></Reference><Reference><Citation>Atzrodt CL, Maknojia I, McCarthy RDP, Oldfield TM, Po J, Ta KTL, et al. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS Journal. 2020;287:3633–3650. doi: 10.1111/febs.15375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15375</ArticleId><ArticleId IdType="pmc">PMC7283703</ArticleId><ArticleId IdType="pubmed">32446285</ArticleId></ArticleIdList></Reference><Reference><Citation>Balloux F, Tan C, Swadling L, Richard D, Jenner C, Maini M, et al. The past, current and future epidemiological dynamic of SARS-CoV-2. Oxf Open Immunol. 2022;3:iqac003. doi: 10.1093/oxfimm/iqac003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqac003</ArticleId><ArticleId IdType="pmc">PMC9278178</ArticleId><ArticleId IdType="pubmed">35872966</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaassen F, Chitwood MH, Cohen T, Pitzer VE, Russi M, Swartwood NA, et al. Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022. Clin Infect Dis. 2023;77:355–361. doi: 10.1093/cid/ciad210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad210</ArticleId><ArticleId IdType="pmc">PMC10425195</ArticleId><ArticleId IdType="pubmed">37074868</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadas SM, Vilches TN, Zhang K, Nourbakhsh S, Sah P, Fitzpatrick MC, et al. Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biol. 2021;19 doi: 10.1371/journal.pbio.3001211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001211</ArticleId><ArticleId IdType="pmc">PMC8092656</ArticleId><ArticleId IdType="pubmed">33882066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Hum Cell. 2021;34:711–733. doi: 10.1007/s13577-021-00512-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13577-021-00512-4</ArticleId><ArticleId IdType="pmc">PMC7937046</ArticleId><ArticleId IdType="pubmed">33677814</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399:924–944. doi: 10.1016/S0140-6736(22)00152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Shioda K, Chen Y, Collins MH, Lopman BA. Population-level relative effectiveness of the COVID-19 vaccines and the contribution of naturally acquired immunity. J Infect Dis. 2023;227:773–779. doi: 10.1093/infdis/jiac483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac483</ArticleId><ArticleId IdType="pmc">PMC10226727</ArticleId><ArticleId IdType="pubmed">36548463</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . World Health Organization; Geneva: 2024. Vaccines and immunization.</Citation></Reference><Reference><Citation>Shet A, Carr K, Danovaro-Holliday MC, Sodha SV, Prosperi C, Wunderlich J, et al. Impact of the SARS-CoV-2 pandemic on routine immunisation services: evidence of disruption and recovery from 170 countries and territories. Lancet Glob Health. 2022;10:e186–e194. doi: 10.1016/S2214-109X(21)00512-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00512-X</ArticleId><ArticleId IdType="pmc">PMC8691849</ArticleId><ArticleId IdType="pubmed">34951973</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . World Health Organization; Geneva: 2022. Interim statement on hybrid immunity and increasing population seroprevalence rates.</Citation></Reference><Reference><Citation>Ylli A, Burazeri G, Wu YY, Sentell T. COVID-19 excess deaths in Eastern European countries associated with weaker regulation implementation and lower vaccination coverage. East Mediterr Health J. 2022;28:776–780. doi: 10.26719/emhj.22.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.26719/emhj.22.074</ArticleId><ArticleId IdType="pubmed">36382733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulcebe G, Ylli A, Kurti-Prifti M, Ylli Z, Shyti E, Dashi-Pasholli J, et al. Rapid increase of SARS-CoV-2 seroprevalence during the second half of the COVID-19 pandemic year 2020 in the adult urban Albanian population. Heliyon. 2023;9:e19547. doi: 10.1016/j.heliyon.2023.e19547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e19547</ArticleId><ArticleId IdType="pmc">PMC10481283</ArticleId><ArticleId IdType="pubmed">37681122</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenko F, Ylli A, Prifti M, Shyti E, Lazri E, Perry MJ, et al. Estimating the seroprevalence of SARS-CoV-2 antibodies: understanding population-level immunity in Albania at the end of the Alpha variant wave. J Glob Health. 2022;12:03054. doi: 10.7189/jogh.12.03054.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.12.03054</ArticleId><ArticleId IdType="pmc">PMC9309000</ArticleId><ArticleId IdType="pubmed">35871412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgson D, Flasche S, Jit M, Kucharski AJ. CMMID COVID-19 Working Group, Centre for Mathematical Modelling of Infectious Disease (CMMID) COVID-19 Working Group. The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant. Euro Surveill. 2021;26 doi: 10.2807/1560-7917.ES.2021.26.20.2100428.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.20.2100428</ArticleId><ArticleId IdType="pmc">PMC8138959</ArticleId><ArticleId IdType="pubmed">34018481</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumel AB, Iboi EA, Ngonghala CN, Ngwa GA. Toward achieving a vaccine-derived herd immunity threshold for COVID-19 in the U.S. Front. Front Public Health. 2021;9 doi: 10.3389/fpubh.2021.709369.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.709369</ArticleId><ArticleId IdType="pmc">PMC8343072</ArticleId><ArticleId IdType="pubmed">34368071</ArticleId></ArticleIdList></Reference><Reference><Citation>Elangovan D, Hussain SMS, Virudhunagar Muthuprakash S, Devi Periadurai N, Viswanath Nalankilli A, Volvoikar H, et al. Impact of COVID-19 vaccination on seroprevalence of SARS-CoV-2 among the health care workers in a tertiary Care Centre, South India. Vaccines (Basel) 2022;10:1967. doi: 10.3390/vaccines10111967.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10111967</ArticleId><ArticleId IdType="pmc">PMC9697367</ArticleId><ArticleId IdType="pubmed">36423062</ArticleId></ArticleIdList></Reference><Reference><Citation>National Agency for Information Society. COVID-19 data repository by the center for systems science and engineering (CSSE) at johns Hopkins university, https://coronavirus.al/statistika/; 2023 [accessed 09 January 2023].</Citation></Reference><Reference><Citation>Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies - United States, September 2021–February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:606–608. doi: 10.15585/mmwr.mm7117e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7117e3</ArticleId><ArticleId IdType="pmc">PMC9098232</ArticleId><ArticleId IdType="pubmed">35482574</ArticleId></ArticleIdList></Reference><Reference><Citation>Awartani F, Qutob NM, Asia MR. Seroprevalence of SARS-CoV-2 antibodies among vaccinated and non-vaccinated adults in the West Bank: results of a repeated cross-sectional study. Vaccines (Basel) 2022;10:1332. doi: 10.3390/vaccines10081332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10081332</ArticleId><ArticleId IdType="pmc">PMC9414774</ArticleId><ArticleId IdType="pubmed">36016220</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones JM, Manrique IM, Stone MS, Grebe E, Saa P, Germanio CD, et al. Estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status - United States, April 2021–September 2022. MMWR Morb Mortal Wkly Rep. 2023;72:601–605. doi: 10.15585/mmwr.mm7222a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7222a3</ArticleId><ArticleId IdType="pmc">PMC10243484</ArticleId><ArticleId IdType="pubmed">37262007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulcebe G, Kurti-Prifti M, Shyti E, Dashi-Pasholli J, Cenko F, Ylli A. Comparative analysis of antibody responses to BNT162b2, ChAdOx1, and CoronaVac vaccines in the Albanian population over the pandemic years 2021 to 2022. Clin Exp Vaccine Res. 2024;13:63–67. doi: 10.7774/cevr.2024.13.1.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2024.13.1.63</ArticleId><ArticleId IdType="pmc">PMC10864881</ArticleId><ArticleId IdType="pubmed">38362369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595:426–431. doi: 10.1038/s41586-021-03696-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03696-9</ArticleId><ArticleId IdType="pmc">PMC8277577</ArticleId><ArticleId IdType="pubmed">34126625</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N Engl J Med. 2022;386:2201–2212. doi: 10.1056/NEJMoa2118946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118946</ArticleId><ArticleId IdType="pmc">PMC9165562</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23:556–567. doi: 10.1016/S1473-3099(22)00801-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. SIREN Study Group. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med. 2022;386:1207–1220. doi: 10.1056/NEJMoa2118691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118691</ArticleId><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrao G, Franchi M, Rea F, Cereda D, Barone A, Borriello CR, et al. Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study. BMC Med. 2022;20:52. doi: 10.1186/s12916-022-02262-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02262-y</ArticleId><ArticleId IdType="pmc">PMC8821854</ArticleId><ArticleId IdType="pubmed">35130877</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, immunity, and COVID-19: how age influences the host immune response to Coronavirus infections? Front Physiol. 2020;11 doi: 10.3389/fphys.2020.571416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.571416</ArticleId><ArticleId IdType="pmc">PMC7835928</ArticleId><ArticleId IdType="pubmed">33510644</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer M, Constancias F, Worth C, Meyer A, Muller M, Boussuge A, et al. Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds. GeroScience. 2022;44:1229–1240. doi: 10.1007/s11357-022-00546-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-022-00546-y</ArticleId><ArticleId IdType="pmc">PMC8990277</ArticleId><ArticleId IdType="pubmed">35394604</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelman B, van der Straten K, Lavell AHA, Schinkel M, Slim MA, Poniman M, et al. Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination. EBiomedicine. 2021;72 doi: 10.1016/j.ebiom.2021.103589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103589</ArticleId><ArticleId IdType="pmc">PMC8461365</ArticleId><ArticleId IdType="pubmed">34571363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley SF, Wei J, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers. Clin Infect Dis. 2021;73:e699–e709. doi: 10.1093/cid/ciab004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab004</ArticleId><ArticleId IdType="pmc">PMC7929225</ArticleId><ArticleId IdType="pubmed">33400782</ArticleId></ArticleIdList></Reference><Reference><Citation>Brochot E, Demey B, Touzé A, Belouzard S, Dubuisson J, Schmit JL, et al. Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals. Front Microbiol. 2020;11 doi: 10.3389/fmicb.2020.584251.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.584251</ArticleId><ArticleId IdType="pmc">PMC7604306</ArticleId><ArticleId IdType="pubmed">33193227</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Elslande J, Oyaert M, Lorent N, Vande Weygaerde Y, Van Pottelbergh G, Godderis L, et al. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagn Microbiol Infect Dis. 2022;103 doi: 10.1016/j.diagmicrobio.2022.115659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2022.115659</ArticleId><ArticleId IdType="pmc">PMC8837483</ArticleId><ArticleId IdType="pubmed">35278794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBiomedicine. 2021;71 doi: 10.1016/j.ebiom.2021.103561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103561</ArticleId><ArticleId IdType="pmc">PMC8390300</ArticleId><ArticleId IdType="pubmed">34455390</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol. 2021;6:eabi6950. doi: 10.1126/sciimmunol.abi6950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abi6950</ArticleId><ArticleId IdType="pmc">PMC8158969</ArticleId><ArticleId IdType="pubmed">33858945</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson M, Stec M, Rewane A, Landay A, Cloherty G, Moy J. SARS-CoV-2 antibody responses in infection-naive or previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine. JAMA Netw Open. 2021;4 doi: 10.1001/jamanetworkopen.2021.19741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.19741</ArticleId><ArticleId IdType="pmc">PMC8346938</ArticleId><ArticleId IdType="pubmed">34357399</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>